- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/10 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 237/10
Total number of patents in this class: 32
10-year publication summary
|
2
|
1
|
2
|
2
|
1
|
5
|
2
|
0
|
1
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Calico Life Sciences LLC | 121 |
3 |
| Abbvie Inc. | 1810 |
2 |
| Ligand UK Development Limited | 32 |
2 |
| Chengdu Hyperway Pharmaceuticals Co., Ltd. | 19 |
2 |
| Shenzhen Zhongge Biological Technology Co., Ltd. | 55 |
2 |
| Glaxo Group Limited | 4361 |
1 |
| Syngenta Participations AG | 1473 |
1 |
| Monsanto Technology LLC | 8583 |
1 |
| Commissariat à l'énergie atomique et aux energies alternatives | 11137 |
1 |
| Korea Institute of Science and Technology | 2269 |
1 |
| Eurofarma Laboratorios S.A. | 38 |
1 |
| Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences | 132 |
1 |
| Ono Pharmaceutical Co., Ltd. | 420 |
1 |
| Sloan-Kettering Institute for Cancer Research | 651 |
1 |
| Tenax Therapeutics, Inc | 19 |
1 |
| Universidade Federal do Rio de Janeiro-ufrj | 99 |
1 |
| Vanderbilt University | 2035 |
1 |
| Xcovery Holdings, Inc. | 22 |
1 |
| Alterity Therapeutics Limited | 11 |
1 |
| Kyowa Kirin Co., Ltd. | 356 |
1 |
| Other owners | 6 |